
Please try another search
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Name | Age | Since | Title |
---|---|---|---|
Paul Y. Song | 58 | 2023 | CEO & Chairman |
Ming Guo | - | 2023 | Member of Scientific Advisory Board |
Michael L. Klowden | 78 | 2023 | Independent Director |
Craig Blackstone | - | 2023 | Member of Scientific Advisory Board |
Kathleen D. Scott | - | 2023 | Independent Director |
Anthony T. Reder | - | 2023 | Member of Scientific Advisory Board |
Marco Gottardis | 67 | 2024 | Independent Director |
Evren Alici | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review